Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO Sells $31,484.53 in Stock

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III sold 9,233 shares of the company’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $3.41, for a total value of $31,484.53. Following the sale, the chief executive officer now owns 3,785,350 shares in the company, valued at approximately $12,908,043.50. This represents a 0.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Checkpoint Therapeutics Trading Down 3.1 %

Shares of NASDAQ:CKPT traded down $0.10 during trading on Tuesday, reaching $3.13. 851,190 shares of the company traded hands, compared to its average volume of 885,885. The firm has a market capitalization of $152.84 million, a price-to-earnings ratio of -1.70 and a beta of 1.36. Checkpoint Therapeutics, Inc. has a 52-week low of $1.38 and a 52-week high of $4.50. The business’s fifty day moving average is $3.39 and its 200-day moving average is $2.99.

Checkpoint Therapeutics (NASDAQ:CKPT) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08). On average, sell-side analysts predict that Checkpoint Therapeutics, Inc. will post -0.94 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Lake Street Capital upped their price target on Checkpoint Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a research report on Monday, December 16th. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Checkpoint Therapeutics in a report on Monday, December 16th. Finally, D. Boral Capital started coverage on Checkpoint Therapeutics in a research note on Monday, January 13th. They issued a “buy” rating and a $9.00 target price for the company.

Institutional Investors Weigh In On Checkpoint Therapeutics

Institutional investors have recently modified their holdings of the stock. Magnus Financial Group LLC boosted its position in shares of Checkpoint Therapeutics by 12.9% during the third quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock valued at $78,000 after buying an additional 4,000 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in shares of Checkpoint Therapeutics by 160.0% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company’s stock worth $291,000 after buying an additional 80,000 shares during the period. Gladstone Institutional Advisory LLC raised its stake in shares of Checkpoint Therapeutics by 141.4% in the third quarter. Gladstone Institutional Advisory LLC now owns 35,000 shares of the company’s stock worth $78,000 after buying an additional 20,500 shares during the period. Walleye Capital LLC bought a new position in shares of Checkpoint Therapeutics in the third quarter worth about $148,000. Finally, State Street Corp raised its stake in Checkpoint Therapeutics by 32.2% during the 3rd quarter. State Street Corp now owns 94,424 shares of the company’s stock valued at $212,000 after purchasing an additional 23,000 shares during the period. 22.00% of the stock is owned by hedge funds and other institutional investors.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.